Table 2.
Cancer patient study population.
| Description | n | % |
| Histology | ||
| Invasive ductal | 27 | 68 |
| Invasive lobular | 2 | 5 |
| Other | 11 | 28 |
| Presenting stage of disease | ||
| I | 5 | 13 |
| II | 15 | 38 |
| III | 8 | 20 |
| IV | 8 | 20 |
| Unknown | 4 | 10 |
| Disease free interval | ||
| 0 | 11 | 28 |
| 1–9 yrs | 19 | 48 |
| 10+ yrs | 9 | 23 |
| Unknown | 1 | 3 |
| Hormone receptor status | ||
| ER+/PR+ | 25 | 63 |
| ER+/PR- | 8 | 20 |
| ER-/PR+ | 1 | 3 |
| ER-/PR- | 3 | 8 |
| Unknown | 3 | 8 |
| HER-2/neu overexpression | ||
| Positive | 4 | 10 |
| Negative | 27 | 68 |
| Unknown | 9 | 23 |
Patient characteristics at time of breast cancer diagnosis (n = 40). Abbreviations: PR, progesterone receptor; ER, estrogen receptor